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https://doi.org/10.1016/j.trsl.2021.0The symbiotic relationships shared between humans and their gastrointestinal para-
sites present opportunities to discover novel therapies for inflammatory diseases. A
prime example of this phenomenon is the interaction of humans and roundworms
such as the hookworm, Necator americanus. Epidemiological observations, animal
studies and clinical trials using experimental human hookworm infection show that
hookworms can suppress inflammation in a safe and well-tolerated way, and that
the key to their immunomodulatory properties lies within their secreted proteome.
Herein we describe the identification of 2 netrin domain-containing proteins from
the N. americanus secretome, and explore their potential in treating intestinal
inflammation in mouse models of ulcerative colitis. One of these proteins, subse-
quently named Na-AIP-1, was effective at suppressing disease when administered
prophylactically in the acute TNBS-induced model of colitis. This protective effect
was validated in the more robust CD4 T cell transfer model of chronic colitis, where
prophylactic Na-AIP-1 reduced T-cell-dependent type-1 cytokine responses in the
intestine and the associated intestinal pathology. Mechanistic studies revealed that
depletion of CD11c+ cells abrogated the protective anticolitic effect of Na-AIP-1.
Next generation sequencing of colon tissue in the T-cell transfer model of colitis
revealed that Na-AIP-1 induced a transcriptomic profile associated with the down-
regulation of metabolic and signaling pathways involved in type-1 inflammation,
notably TNF. Finally, co-culture of Na-AIP-1 with a human monocyte-derived M1
macrophage cell line resulted in significantly reduced secretion of TNF. Na-AIP-1 is
now a candidate for clinical development as a novel therapeutic for the treatment
of human inflammatory bowel diseases. (Translational Research 2021; 232:88102)tics Ltd, Suite 1.11, Level 1, 1 Westlink Court, Brisbane, QLD 4076, Australia.
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Background
Inflammatory bowel diseases (IBD) are debilitating
and chronic conditions that are caused by uncon-
trolled inflammation in the intestine. Existing treat-
ments are often poorly tolerated and minimally
effective. In the search for new anti-inflammatory
therapeutic modalities, we took inspiration from the
co-evolution of humans parasitic worms (helminths).
Translational Significance
Herein we show that gastrointestinal hookworms
secrete a netrin protein that limits IBD symptoms
and gut inflammation when delivered prophylacti-
cally in multiple mouse models of IBD. Na-AIP-1
administration suppresses several inflammatory
pathways within mouse gut tissue and a human
macrophage cell line, and could be further devel-
oped as a safe and efficacious maintenance ther-
apy for human IBD.INTRODUCTION
Inflammatory bowel disease (IBD) is a blanket term
describing Crohn’s disease (CD), ulcerative colitis
(UC) and a handful of less common, but similarly
debilitating, inflammatory conditions of the gastroin-
testinal tract. IBDs are chronic, refractory disorders
that are classified in accordance with the nature of their
respective immunological and pathological features;
ultimately, the disorders are characterized by compro-
mised epithelial barrier integrity and hyper-responsive
inflammatory conditions. An increase in the incidence
of IBDs in developing countries, combined with their
existing prevalence in industrialized nations, has led to
its emergence as a global disease of significant bur-
den.1 However, effective medical management of IBD
remains elusive; whilst treatments exist, they are often
poorly tolerated or of limited effect, underlining a need
for the development of novel therapeutic modalities.Various studies have documented the efficacy of live
helminth infection in the alleviation of the signs and symp-
toms associated with inflammation in both human gastroin-
testinal inflammatory diseases and animal models of
colitis.26 Despite being well tolerated, inconsistent data
has resulted from experimental human infection trials in
patients with IBD,78 and numerous hurdles complicate
the adoption of live parasitic infection as a valid anti-
inflammatory therapy.8 As an alternative, the use of hel-
minth-derived products has been explore.9 Excretory/secre-
tory (ES) products from the canine hookworm
Ancylostoma caninum prevented inflammation in chemi-
cally induced TNBS colitis, a model of Crohn’s disease
where the pathology is driven by T-cell dependent mecha-
nisms.10 At termination, indicators of macroscopic inflam-
mation and myeloperoxidase activity in the colons of A.
caninum ES-treated mice showed significant abatement,
accompanied by a reduction in the expression of Th1 cyto-
kines and a skewing towards a modified Th2 environment.
Hookworm ES products have also been shown to impart
efficacy in a T cell-independent model of murine coli-
tis,11,12 as well as other mouse models of immune dysfunc-
tion diseases.13 Together, these studies demonstrated the
potential of therapeutic immunomodulation by hookworm
ES products in the absence of live parasitic infection.
The characterization of the transcriptomes14,15 and
genomes16,17 of several hookworm species has enabled
deeper investigation into the components of the helminth
secretome. Two of the most abundant proteins in the A.
caninum secreted proteome  Ac-AIP-1 and Ac-AIP-
21821 contain netrin domains and share sequence similar-
ity with mammalian tissue inhibitors of matrix metallopro-
teases (TIMPs). Netrin domains are central to TIMPs and
contain the active site N-terminal domain that confers
MMP-inhibitory activity.22 The hookworm TIMP-like
proteins AceES-223 and Ac-AIP-213 display TIMP-like
sequence and predicted structure, but lack defined residues
involved in inhibition of MMP catalytic activity.23,24
Moreover, netrin domains are involved in diverse pro-
cesses from axonal guidance, morphogenesis and angio-
genesis by regulating cell migration and survival.25
Recombinant Ac-AIP-2 was demonstrated to bind to
mesenteric CD103+ dendritic cells and drive expansion of
regulatory T cells (Tregs) that suppressed inducible
asthma in mice and down regulated the expression of co-
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cells from asthmatic subjects.13 The homologous Ac-AIP-
1 protein was subsequently shown in recombinant form to
suppress proinflammatory responses in the TNBS model
of chemically-induced murine colitis.26 Cantacessi and
colleagues24 identified several homologues of these
TIMP-like proteins in helminths which primarily parasit-
ize humans. It is plausible that, with humans as a natural
host, netrin domain-containing proteins from these species
may not only display anti-inflammatory properties, but
may be better adapted to modulate human immune func-
tion. Accordingly, two potential netrin domain-containing
proteins from the ES products of the major human hook-
worm, Necator americanus, were identified for further
investigation. Herein we describe recombinant production
of two novel netrin domain-containing proteins isolated
from the N. americanus secretome, and the anti-colitic
properties of one of them, Na-AIP-1, in acute and chronic
models of colitis.MATERIAL AND METHODS
N. americanus netrin domain-containing proteins. Ne-
trin domain-containing proteins Na-AIP-1 and
NECAME_13168, from the intra-mammalian stages of
N. americanus, were identified by Cantacessi et al.24
Briefly, genome data for N. americanus was analyzed
with known TIMP amino acid sequences from Homo
sapiens (GenBank accession numbers XP_010392.1,
NP_003246.1, P35625.1 and Q99727.1) and Ac-AIP-2
(EU523696.1) using BLASTp and InterProScan algo-
rithms. TIMP-like proteins were then further assessed
for an N-terminal signal peptide and netrin domain.
Secondary structural predictions were conducted using
MOLMOL 2K.127 and I-TASSER molecular graphics
software.28 H. sapiens TIMP-2 was the closestFig 1. Superposition of hookworm TIMP-like proteins on h
prot W2TPY4), NECAME_13168 (W2SWZ9) and Ancylo
3NSW) were modelled on the crystal structure of Homo sapi
Superposition of Na-AIP-1 (green) on H. sapiens TIMP 2 (r
respectively. B, Superposition of NECAME_13168 (aqua)
81-100 and 96-115 respectively. C, Superposition of AceES
residues 83-100 and 101-118, respectively. Modeling was cohomologue with known structure and accordingly this
protein was used as the backbone on which to build the
models (Fig 1).
Recombinant protein expression. cDNA sequences
corresponding to the open reading frames (ORFs) were
cloned without signal peptides (Na-AIP-1 residues 18
to 139; NECAME_13168 residues 18 to 134) into the
EcoRI and XbaI sites of the pPIC-Z-alpha plasmid
(Invitrogen). Two extra base pairs were added to the C-
terminal end of the sequences to maintain the reading
frame and ensure translation of the c-myc and 6xHIS
tags. These extra bp resulted in a glycine being added
to the C-terminus upstream of the vector-derived tags
within pPIC-Z-alpha. Recombinant proteins were
expressed via secretion using the yeast Pichia pastoris.
Recombinant proteins were isolated from the yeast cul-
ture supernatant using immobilized metal ion affinity
chromatography (IMAC) on an €AKTA FPLC chroma-
tography system with a 5 mL HisTrap excel nickel col-
umn (GE Healthcare Life Sciences). Endotoxin
removal was conducted using an EndoTrap HD Endo-
toxin Removal System (Hyglos) according to the man-
ufacturer’s instructions. Recombinant human albumin
(HA) was expressed and purified in P. pastoris under
identical conditions to the hookworm proteins, as indi-
cated above.
Mice and ethics. Male BALB/c, male SJL/Jarc, male
and female C57BL/6 mice and male B6.SVJ129-Rag1
(RAG KO) mice aged 5-7 weeks were obtained from
Animal Resources Centre (Murdoch, Australia) or Aus-
tralian BioResources (Moss Vale, Australia). Male and
female C57BL/6.CD11c.DTR aged 6+ weeks, were
bred in the JCU Small Animal Facility (Townsville,
Australia). Mice were maintained in specific pathogen-
free conditions in a temperature-controlled room with a
12 hour light/dark illumination cycle and received auto-
claved food and water ad libitum. Animals were alloweduman TIMP-2. Necator americanus Na-AIP-1 (Uni-
stoma ceylanicum AceES-2 (Q6R7N7, PDB code
ens TIMP-2 (Uniprot P16035; PDB code 1BR9). A,
ed) superimposed over residues 81-115 and 95-129
on H. sapiens TIMP 2 superimposed over residues
-2 (blue) on H. sapiens TIMP-2 superimposed over
nducted using Modeller and I-TASSER.28.
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mental interventions. Mice were sacrificed via CO2
asphyxiation. Experiments were approved by the James
Cook University Animals Ethics Committee under
Ethics Approval numbers A2012 and A2379 and con-
ducted in accordance with National Health and Medical
Research Council Australian Code for the Care and Use
of Animals for Scientific Purposes (8th Edition, 2013)
and in compliance with the Queensland Animal Care
and Protection Act, 2001 (Act No.64 of 2001).
Treatment administration. Mice were randomly
divided into treatment groups of 5 per cage, with an
even split between sexes where relevant. Na-AIP-1,
NECAME_13168, HA control was administered by
intra-peritoneal (i.p.) injection at a dose of 1 mg/kg
body weight, in PBS vehicle (200 mL total injection
volume). The recombinant protein dosage level of
1 mg/kg and route of delivery was determined in con-
sideration with results from similar studies.1013 Con-
trol mice received PBS vehicle only. aIL12/23 mAb
(clone C17.8, BioxCell) was administered at a dose of
1 mg/mouse per week.
CD11c+ cell depletion. C57BL/6 and C57BL/6.
CD11c.DTR mice received 500 ng diphtheria toxin
(Sigma-Aldrich) as indicated. Depletion of CD11c+
cells was confirmed by comparing CD3- CD19-
CD11c+ MHCII+ cell frequency in the live mesenteric
lymph node (mLN) cells between WT and DTR mice.
TNBS-induced colitis. Colitis was induced via intra-
rectal injection of 100 mL 1.5 mg TNBS in 50% EtOH
in BALB/c mice, and 50 mL 1.5 mg TNBS in 50%
EtOH in SJL/Jarc mice, as described elsewhere.29
TNBS administration was conducted on day zero of the
experimental period unless otherwise indicated.
T cell transfer colitis. Colitis was induced in RAG KO
mice using established protocols.3031 Briefly, spleens
were harvested from C57BL/6 WT donor mice and CD4
+ cells were isolated by negative selection via magnetic
separation, using the EasySep CD4+ T Cell Isolation kit
(Stemcell Technologies) as per manufacturer’s instruc-
tions. Enriched CD4 cells were labeled with APC-anti-
mouse CD4 (clone RM4-5; BD Biosciences) and FITC-
anti-mouse CD25 (clone AL-21; BD Biosciences) and
sorted into CD4+ CD25- fractions on a BD FACSAria
III. Each RAG KO mouse received 100 mL of PBS con-
taining 4£ 104 purified CD4+ CD25- cells by i.p. injec-
tion on day 0. Naı̈ve control RAG KO mice did not
receive donor CD4 cells.
Clinical and macroscopic disease scores. Mice were
assessed daily (TNBS experiments) or twice weekly (T
cell transfer experiments) for clinical signs of disease
and scored using criteria adapted from Ruyssers et al.10
Piloerection and lethargy, diarrhea and rectal thicken-
ing/bleeding were graded according to severity from 0(absent) to 2 (severe), to a maximum cumulative total
score of 6. At necropsy, colons were removed, flushed
with PBS and assessed for length and macroscopic
signs of disease utilizing criteria adapted from Ruyss-
ers et al.10 Adhesion, edema and thickening were
graded according to severity from 0 (absent) to 2
(severe), and ulceration was graded from 0 (absent) to
necrosis (3), to a maximum cumulative total score of 9.
Histological analysis of distal colon tissue. Distal colon
tissue was harvested in 1 cm sections and fixed in 4%
formalin overnight, whereupon tissue was transferred
to 70% EtOH. Embedding of tissue in paraffin, hema-
toxylin and eosin (H/E) staining was performed at the
QIMR Berghofer Medical Research Institute histology
facility (Brisbane, Australia) or the Advanced Analyti-
cal Centre, James Cook University (Cairns, Australia).
Photomicrographs of tissue sections were scored by a
researcher blinded to experimental group on a scale of
0-5 for each of the following parameters; (1) epithelial
pathology (crypt elongation, hyperplasia, and erosion),
(2) mural inflammation and (3) edema for an overall
maximal total histology score of 15.
Cytometric bead array (CBA). Cytokine detection was
conducted on whole colon tissue homogenate (500 mL
PBS/1 cm tissue) using a BD Mouse Inflammation
CBA kit (BD Biosciences), as per the manufacturer’s
instruction. Visualization and analysis of CBA was
conducted using FCAP Array software version 3.0.
Gene expression analysis. In a representative T cell
transfer experiment, groups of 4 mice treated with either
PBS, aIL12/23 or Na-AIP-1 were sacrificed at day 27
and colon tissues processed for RNAseq analysis. At ter-
mination, colons were removed and cleaned in sterile
PBS. One cm sections of distal colon were collected into
RNAlater (Sigma-Aldrich) on ice. Total RNA was
extracted from macerated whole colon tissue using the
RNeasy Plus Mini Kit (QIAGEN) according to the man-
ufacturer’s protocol and stored at 80˚C. Sequencing
libraries were prepared using TruSeq Stranded mRNA
Library Prep Kit (Illumina) and sequenced by the Austra-
lian Genomics Research Facility (AGRF, Melbourne,
Australia). Paired-end sequencing to generate a read
length of 150 bp was conducted using NovaSeqS4.
Adapter sequences were trimmed using Cutadapt version
1.9132 and trimgalore version 0.5.0_dev (https://www.
bioinformatics.babraham.ac.uk/projects/trim_galore/).
Data quality control was performed using FastQC
(https://www.bioinformatics.babraham.ac.uk/projects/
fastqc/). STAR version 2.7.0a33 was utilized for read
alignment, with alignment to the murine reference
genome mm10 (ftp.ensemble.org/pub/release-90/fasta/
mus_musculus/dna/). Data normalization using EDASeq
version 2.20.,34 RUV correction,35 principle component
analysis (PCA), and differential gene expression analysis
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package36 in R version 3.6.2, and results from edgeR ver-
sion 3.28.037 are reported. When assessing differentially
expressed genes (DEGs), those with a log2-fold change
(LFC) of 0.5 to 0.5 were excluded. An edgeR FDR-
adjusted P value <0.05 was considered significant.38
Differential gene expression analyses were conducted
between colitic mice receiving PBS, colitic mice receiv-
ing aIL12/23, and colitic mice receiving Na-AIP-1. Vol-
cano plots depicting DEGs were constructed in R using
plotting functions in the graphics package version 3.6.2.
THP-1 derived M1 macrophages. M1 macrophages
derived from the human THP-1 monocyte cell line were
obtained as described elsewhere39 with some modifica-
tions. THP-1 cells were resuspended in R-10 medium
containing 200 nM phorbol 12-myristate 13-acetate
(PMA) (Sigma) and cultured at 1£ 105 cells per 100 mL
per well in flat-bottom 96-well plates. After 48 hours the
cells were washed with PBS and the medium replaced
with R-10 (without PMA). After 24 hours of PMA starva-
tion, the resulting M0 macrophages were polarized by
replacing the medium with R-10 containing 20 ng/mL
human recombinant IFNg and 2 ng/mL human recombi-
nant TNF (PeproTech). Forty-eight hours later the cells
were washed and the media replaced with R-10 contain-
ing either 100 mg/mL Na-AIP-1 or an equivalent volume
of PBS (vehicle control). The cells were stimulated with
10 ng/mL LPS (Sigma) and soups were collected 24
hours later and analysed using a LEGENDplex (BioLe-
gend) kit.
Statistical analyses. Statistical analyses were con-
ducted using GraphPad Prism 8 software. Comparisons
between all groups were conducted using unpaired,
one-way ANOVA (Holm Sidak) unless otherwise spec-
ified. Comparisons between individual groups were
performed by unpaired, two-way Mann-Whitney U
tests (Holm Sidak), vs negative/vehicle control, unless
otherwise specified. Comparisons between all groups
at multiple time points were conducted using unpaired,
two-way ANOVA (Holm Sidak) unless otherwise spec-
ified. Comparisons between individual groups were
performed by unpaired, two-way Mann-Whitney U
tests (Holm Sidak), vs negative/vehicle control, unless
otherwise specified. Significance levels were set at a P
value of  0.05.RESULTS
Netrin domain-containing proteins of N. americanus.
TIMP-like proteins Na-AIP-1 and NECAME_13168,
from the infective L3 stage of N. americanus, were
identified by Cantacessi et al.24 Briefly, genome data
for N. americanus was analyzed with known TIMPamino acid sequences from Homo sapiens (GenBank
accession numbers XP_010392.1, NP_003246.1,
P35625.1 and Q99727.1) and Ac-AIP-2 (EU523696.1)
using BLASTp and InterProScan algorithms. TIMP-
like proteins were then further assessed for an N-termi-
nal signal peptide and netrin domain. Netrin domains
are central to TIMPs and contain the active site N-ter-
minal domain that confers MMP-inhibitory activity.22
The hookworm TIMP-like proteins AceES-223 and Ac-
AIP-213 display TIMP-like sequence and predicted
structure, but lack defined residues involved in inhibi-
tion of MMP catalytic activity.23,24 H. sapiens TIMP-2
was the closest homologue with known structure and
accordingly this protein was used as the backbone on
which to build the models (Fig 1).
Expression of recombinant N. americanus proteins. Re-
combinant Na-AIP-1 migrated at the expected size
(377 bp, 16.2 kDa) of the mature protein after proteo-
lytic processing of the signal peptide under denaturing
and reducing conditions (Figure S1). Yeast culture
supernatant of 500 mL produced a yield of recombinant
Na-AIP-1 of 47.4 mg with an endotoxin concentration
of 0.74 EU/mg protein, and a yield of recombinant
NECAME_13168 of 11.4 mg with an endotoxin con-
centration of 3.73 EU/mg protein. Both proteins had
endotoxin concentrations that were within the limits of
cell culture applications.
Prophylactic delivery of recombinant Na-AIP-1 limits
clinical and pathological determinants of TNBS-induced
colitis. To examine the potential efficacy of Na-AIP-1 and
NECAME_13168 in murine colitis, we first employed an
8-day model of acute TNBS-induced colitis. BALB/c mice
received i.p. injections of Na-AIP-1, NECAME_13168 or
HA on days -1, 2 and 5 and were challenged twice by
intrarectal administration of TNBS on days 0 and 6, and
sacrificed at day 8 (Fig 2, A). The rationale of double
TNBS administration was used in consideration with estab-
lished protocols, and employed to reflect in a more robust
fashion the active and remitting nature of colitic Th1
inflammation observed in human CD.40-41 Furthermore,
this approach enabled the characterization of treatment effi-
cacy in both acute (<48 hours postchallenge) and subacute
(>48 hours postchallenge) conditions. Mice treated with
HA experienced rapid bodyweight loss within 48 hours of
TNBS administration, followed by a slow recovery of
weight (Fig 2, B). While treatment of mice with
NECAME_13168 did not affect this weight loss, treatment
with Na-AIP-1 resulted in significantly reduced initial
weight loss and a rapid recovery of weight by day 3, simi-
lar to mice treated with aIL12/23 mAb (Fig 2, B). Na-
AIP-1 and aIL12/23 mAb also displayed reduced weight
loss compared to HA control mice after the second TNBS
administration. Consistent with protection against weight
loss, mice treated with Na-AIP-1 or aIL12/23 also
Fig 2. Prophylactic delivery of recombinant Na-AIP-1 limits clinical and pathological determinants of TNBS-induced
colitis. A, Mice received intraperitoneal injections of 1 mg/kg body weight of Na-AIP-1, NECAME_13168 (N_13168)
or recombinant human albumin (HA) control on days1, 2 and 5. aIL12/23 mAb (clone C17.8, BioxCell) was admin-
istered at a dose of 1 mg/mouse per week. Mice were received an intrarectal administration of TNBS on days 0 and 6.
B, Relative change in body weight compared to baseline. C, Clinical scores of colitis. D, Colon length at termination. E,
Representative images of colon tissue in each group. F, Macroscopic scores of colon tissue pathology. G, Blinded histo-
logical scoring of distal colon tissue pathology. H, Representative photomicrographs of H&E stained distal colon sec-
tions from each group. Annotations indicate inflammatory pathology, including loss of normal epithelial barrier
structure (black arrow), lymphocytic infiltration of the lamina propria (white arrow) and thickening of the muscularis
(blue arrow). Experiment was performed twice (n = 5 per treatment group); representative results from a single experi-
ment are shown. Data are presented as mean § SEM. Comparisons were conducted using one-way ANOVA (Holm-
Sidak), two-way ANOVA or Mann Whitney t test (nonparametric) where appropriate, *P  0.05, **P  0.01, ***P
0.001 compared to HA group.
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ease compared to HA-treated mice, while
NECAME_13168 was not protective (Fig 2, C). We next
examined the effect of Na-AIP-1 and NECAME_13168
on macroscopic and histological pathology in the colon
upon termination of the TNBS experiment. Consistent
with reduced colitis, mice treated with Na-AIP-1 displayed
significantly longer colons than HA treated mice (Fig 2,
D), where colons visually appeared similar to the appear-
ance of naı̈ve mice that were not treated with TNBS (Fig
2, E). Macroscopic scoring of inflammatory pathology
revealed that both Na-AIP-1 and aIL-12/23, but not
NECAME_13168, significantly reduced macroscopic
pathology compared to the HA group (Fig 2F). Similarly,
blinded analysis and scoring of distal colon tissue sections
demonstrated that aIL-12/23 and Na-AIP-1 treatment sig-
nificantly reduced colon histopathology scores compared
to HA control mice (Fig 2, G). While mice treated with
HA or NECAME_13168 displayed considerable morpho-
logical corruption, with diffuse transmural lymphocytic
infiltration, disruption of normal epithelial barrier integrity
and loss of goblet cells, mice receiving Na-AIP-1 or
aIL12/23 displayed normalized colon appearance, similar
to naı̈ve mice (Fig 2, H). Together, these data suggest that
prophylactic delivery of Na-AIP-1 is effective at limiting
disease in acute TNBS colitis, similar to IL-12/23 neutrali-
zation, an approved human colitis therapy.42
We next examined whether Na-AIP-1 exerts similar
efficacy when delivered therapeutically, that is, after
disease onset has occurred. To do this, we employed a
short 3-day colitis model, where BALB/c mice were
challenged with intrarectal TNBS on day 0, and treated
with Na-AIP-1 i.p. on either day 1 (prophylactic) or
day 1 or day 2 (therapeutic) (Fig S3A). As expected,
prophylactic delivery of Na-AIP-1 was able to reduce
weight loss, clinical score and increase colon length
compared to mice treated with PBS vehicle only (Fig
S3B-D). Therapeutic treatment of mice with Na-AIP-1
one day after TNBS resulted in a similar level of pro-
tection to prophylactic treatment, but treatment at day
2 did not result in any suppression of disease parame-
ters compared to PBS treatment (Fig S3B-D). These
results suggest that Na-AIP-1 has limited therapeutic
ability to suppress active colitis and may be most effec-
tive when provided therapeutically.
Na-AIP-1 limits gut pathology and inflammatory
responses in a T-cell transfer model of colitis. We next
examined whether Na-AIP-1 also displayed efficacy at
limiting disease in a more chronic, immunologically
driven model of colitis that closely mirrors human dis-
ease.43 We employed a T cell transfer model of colitis
where C57BL/6 RAG KO mice received CD4+ CD25-
cells from wildtype C57BL/6 mice i.p, a model used in
multiple previous studies where the transferred cellpopulations are a mixture of naive and non-Treg memory
T cells.31,44-46 Mice were treated with either Na-AIP-1 or
HA control twice per week (Fig 3, A). Control mice
received aIL12/23 mAb once per week, which has been
shown to suppress T cell transfer colitis,43 and naı̈ve con-
trol mice received no cell transfer. As expected, treatment
of mice with the negative control protein HA displayed
signs of colitis starting at day 21, including weight loss
between days 18-25 (Fig 3, B) and increased clinical signs
of disease that peaked at day 25 (Fig 3, C). In contrast,
mice treated with aIL12/23 or Na-AIP-1 did not lose
weight and had significantly reduced clinical scores com-
pared to HA control mice (Fig 3, B-C). Consistent with
reduced induction of colitis, the colons of mice receiving
aIL12/23 or Na-AIP-1 were significantly longer than
those of HA-treated mice (Fig 3, D) and displayed less-
ened macroscopic evidence of colitis, such that colons
resembled those of naive mice (Fig 3, E). Blinded grading
of distal colon tissue sections demonstrated that aIL12/23
or Na-AIP-1 treatment significantly reduced colon histo-
pathology scores compared to HA control mice (Fig 3F),
where HA-treated mice displayed epithelial hyperplasia,
dense leukocyte infiltration in the lamina propria, and
goblet cell loss that was not observed in aIL12/23 or Na-
AIP-1-treated mice (Fig 3, G).
Targeted depletion of CD11c+ cells limits the anti-
inflammatory influence of Na-AIP-1. Since the homolo-
gous Ac-AIP-2 protein is known to utilize mesenteric
DCs in the suppression of induced asthma,13 we next
assessed whether ablation of CD11c+ cell populations
would inhibit the function of Na-AIP-1 in an inflamma-
tory setting. We utilized mice engineered to express a
high-affinity simian diphtheria toxin receptor on
CD11c-bearing cells (CD11c-DTR), enabling targeted
depletion of these cells by administration of human
diphtheria toxin. Mice were then subjected to a 9-day
TNBS colitis protocol (Fig 4, A). Recombinant Na-
AIP-1 or HA treatment was delivered 24 hour prior and
24 hour post each TNBS challenge. All mice received
500 ng of diphtheria toxin on days 1, 4, and 8 to
ensure consistent depletion of CD11c+ macrophages
and dendritic cells, which was confirmed by flow cyto-
metric analysis of reduced CD11c+ MHCII+ cells in
the mLN of DTR+ mice (Fig 4, B). As expected, TNBS
administration to WT mice and treatment with HA con-
trol resulted in rapid weight loss (Fig 4, C) and
increased clinical score (Fig 4, D) that was slow to sub-
side, and similar to that seen in CD11c+ cell-depleted
DTR+ mice. Also as expected, Na-AIP-1 treatment of
CD11c-sufficient WT mice resulted in rapid recovery
from weight loss, and reduced clinical scores between
days 5-6 post-TNBS compared to the control group,
although low sample size prevented statistical signifi-
cance. However, Na-AIP-1 did not protect against
Fig 3. Na-AIP-1 limits gut pathology and inflammatory T cell responses in a T cell transfer model of colitis. A,
Mice were injected with 4£ 104 CD4+ CD25- T cells via intraperitoneal (i.p.) injection on day 0, and were
treated twice weekly with either Na-AIP-1 or HA control, or aIL12/23 mAb once weekly via i.p. injection. B,
Relative change in body weight compared to baseline. (C, Clinical scores of colitis. D, Colon length at termina-
tion. E, Representative images of colon tissue in each group. F, Blinded histological scoring of distal colon tis-
sue pathology. G, Representative photomicrographs of H&E stained distal colon sections from each group. Data
are presented as mean § SEM. Experiment was performed three times (n = 5 per treatment group); representa-
tive results from a single experiment are shown. Comparisons were conducted using two-way RM ANOVA
(Holm-Sidak) or Mann Whitney t-test (nonparametric) where appropriate. * P  0.05, ** P  0.01, **** P 
0.0001 compared to HA group.
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DTR mice (Fig 4, C-D). These results were consistent
with terminal colon length and macroscopic score
parameters, which showed that Na-AIP-1 administra-
tion significantly protected against colon shortening
(Fig 4, E) and macroscopic disease (Fig 4, F) in WT
mice, but not in CD11c-depleted DTR mice. Visual
inspection of the colons of mice at termination
highlighted the striking disparity between Na-AIP-1
(WT) and Na-AIP-1 (DTR) mice, with the latter show-
ing high degrees of edema and distal necrosis (Fig 4,
G). The outcome of these studies suggests Na-AIP-1
requires the presence of CD11c+ cells in order to exert
an anticolitic effect in the TNBS model.
Differentially expressed genes in the colon of mice
treated with Na-AIP-1 during T cell transfer colitis.We nextaimed to further investigate the potential mechanism of
action of Na-AIP-1 during colitis by investigating the
colon tissue-specific biological effects in treated mice
using RNA sequencing, and comparing with aIL12/23
treatment where the mechanism of action is well under-
stood. We employed the same T cell transfer model of
colitis as described in Fig 3, however in this experiment
mice were sacrificed at day 27 when all PBS vehicle con-
trol-treated mice showed clinical indications of colitis,
but Na-AIP-1-treated and aIL12/23-treated mice dis-
played limited disease (Fig S2). The PCA plot exhibits a
clear separation in gene expression profiles between treat-
ment groups, and recognizable clustering of biological
replicates within treatment groups (Fig 5, A). In order to
determine the magnitude of transcriptional alterations
generated in T cell transfer colitis, we measured
Fig 4. Targeted depletion of CD11c+ cells limits the anti-inflammatory influence of Na-AIP-1 in TNBS colitis.
A, Beginning on day 1, C57BL/6 WT or CD11c-DTR mice were treated intraperitoneally with either Na-AIP-
1 or HA control and challenged twice by intrarectal administration of TNBS on days 0 and 7. B, CD11c+ cells
were depleted by diphtheria toxin (DT) treatment, which was confirmed by flow cytometry analysis of frequen-
cies of CD11c+MHCII+ cells in the mesenteric LN. C, Relative change in body weight compared to baseline.
D, Clinical scores. (E, Colon length at termination. F, Macroscopic scores of colon tissue pathology. G, Repre-
sentative images of colon tissue in each group. Data are presented as mean § SEM; * P  0.05 compared to Na-
AIP-1-treated WT, two-way unpaired Mann-Whitney test. Experiment was performed three times (n = 5 per
treatment group, n = 2 per naı̈ve group); representative results from a single experiment are shown.
Translational Research
96 Buitrago et al June 2021
Fig 5. RNAseq profiling of differentially expressed genes in the colons of mice treated with Na-AIP-1 during T cell
transfer colitis. Colitis was induced in RAG KO mice by adoptive transfer of CD4+ CD25- T cells on day 0. Mice
received PBS, aIL12/23 or Na-AIP-1 twice per week by intraperitoneal injection. Termination was conducted at day
27, when all vehicle control (PBS) mice displayed clinical indicators of colitis. RNA-seq was conducted on distal colon
sections and transcriptomic expression profiles compared. A, PCA exhibits a clear separation in gene expression profiles
between treatment groups, recognisable clustering of biological replicates within treatment groups, and a distinct separa-
tion between treatment groups. B, Comparison of aIL12/23 expression with the vehicle control identified 5,773 DEGs,
of which 64% were downregulated. Prophylactic administration of Na-AIP-1 induced 2,360 DEGs, of which 69% were
downregulated in comparison to the PBS control. Data and images were generated using the consensusDE package in
R.38 (C) Bar chart illustrating the top 25 downregulated (blue) and upregulated (red) DEGs in Na-AIP-1-treated mice
compared to PBS. D, Top 20 KEGG pathways associated with genes differentially expressed in Na-AIP-1-treated mice
compared to PBS. Only pathways with 2 hits have been included to ensure biological relevance. Terms are listed by
rank. Frequency of all DEGs within the treatment group that are annotated to the respective term are represented as
genes in pathway (%). Images were constructed in R using plotting functions in the graphics package version 3.6.2. or
ggplot2_3.2.1.52 Ellipses represent 80% confidence level. Results from a single experiment are shown (n = 4 per treat-
ment group).
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Fig 6. Na-AIP-1 suppresses expression of genes involved in
mouse and human TNF signaling. A, Colitis was induced in
RAG KO mice by adoptive transfer of CD4+ CD25- T cells on
day 0. Mice received PBS or Na-AIP-1 twice per week by intra-
peritoneal injection. Termination was conducted at day 27, when
all vehicle control (PBS) mice displayed clinical indicators of
colitis. RNA-seq was conducted on distal colon sections and
transcriptomic expression profiles of genes involved in TNF sig-
naling (KEGG) were analyzed. Forty-three genes in this pathway
underwent significant downregulation when log2 fold-change
was analyzed using EDGE_R. Heatmap was generated using
Graphpad Prism 8. B, Human THP-1 derived M1 macrophages
were stimulated for 24 hours with 10 ng/mL LPS in the presence
of PBS (vehicle control, black bar) or 100 mg/mL Na-AIP-1
(grey bar). TNF release was analysed using the Legendplex
assay. Each symbol represents a technical replicate. Data from
one experiment is shown, and a second independent experiment
analysed by ELISA resulted in a similar outcome. *** P <
0.001 (unpaired t test).
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aIL12/23p40 antibody, the benchmark for the induction
of remission in the adoptive transfer model of murine
colitis,43 to the PBS-treated control. This comparison
revealed 2057 upregulated genes and 3716 significantly
downregulated genes in aIL12/23 mice compared to PBS
treated mice (Fig 5, B). When comparing the transcrip-
tional profile of mice treated with Na-AIP-1 to the PBS
vehicle control, a total of 2,360 genes were differentially
expressed. Of these, 721 genes were significantly upregu-
lated and 1639 were significantly downregulated (Fig 5,
B). Four of the top 7 most highly downregulated genes in
the gut of Na-AIP-1-treated mice were granzymes (Fig 5,
C), programmed cell death-inducing serine proteases
released by cytoplasmic granules within cytotoxic T cells
and NK cells. This was reflected in the KEGG pathway
analysis where differentially expressed genes were signif-
icantly enriched for NK cell-mediated cytotoxicity, as
well as related pathways such as NF-kappa B signaling,
TNF signaling, T-cell receptor signaling and cytokine-
cytokine receptor signaling pathways were also signifi-
cantly downregulated (all FDR adjusted P-values< 0.05;
Fig 5, D). KEGG pathways that were significantly upre-
gulated in Na-AIP-1-treated mice compared to PBS-
treated colitic mice received lower P values and generally
had fewer genes affected within each pathway (Fig 5, D).
Moreover, many of the upregulated pathways in Na-AIP-
1-treated mice were involved in various metabolism pro-
cesses, amino and fatty acid degradation processes, and
steroid hormone biosynthesis. Two of the most highly
upregulated genes in Na-AIP-1-treated mice were the
dendritic cell C-type lectin receptors, Cd209g and Cd209f
(Fig 5, C). Comparison of DEGs between mice treated
with Na-AIP-1 and aIL-12/23 revealed 20 genes in which
transcription was upregulated by Na-AIP-1 but not
aIL12/23, and 76 genes in which transcription was exclu-
sively downregulated by Na-AIP-1 (Fig S4). Genes which
underwent the greatest change in expression levels that
were exclusive to Na-AIP-1 were dominated by a down-
regulation in those related to cytotoxic T cell and NK cell
granulation (Gzmd, Gzmg, Gzmf) and T cell receptor
alpha chain components (Trav6n-6, Trav9d-3, Trav9n-3,
Trav14n-3). Genes with a log fold change (LFC) between
1 and1 were excluded to ensure biological relevance.
Na-AIP-1 reduces expression of TNF signaling pathway
genes in mouse and human tissues. Genes involved in
the TNF signaling pathway (KEGG mmu04668) were
analyzed from the RNA-seq dataset for mice treated
with Na-AIP-1 and vehicle. Almost half the genes in
this pathway (43 genes), including Tnf and other
inflammatory cytokines such as Il6 and Il1, underwent
significant downregulation when log2 fold-change was
analyzed using EDGE_R (Fig 6, A). To determine
whether suppression of TNF was also detected inhuman tissue, recombinant Na-AIP-1 was co-cultured
with human THP-1 derived M1 macrophages for 24 h
with LPS in the presence of PBS vehicle or recombi-
nant Na-AIP-1. In 2 separate experiments, significant
suppression of TNF release was detected using both
the Legendplex assay and ELISA (P< 0.001) using an
unpaired t test (Fig 6, B).
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As the burden of conditions driven by inappropriate
immune responses continues to grow, the need for
effective therapeutic interventions has become more
critical. The unique symbiotic relationship shared
between human and helminth has presented the oppor-
tunity for the discovery of a pharmacopoeia of novel
biologics, which come with the advantage of a favor-
able tolerability profile afforded by centuries of host-
parasite co-evolution. N. americanus, in particular, is
exquisitely well adapted to reside within the human gut
for several years, without instigating the inflammatory
response anticipated against a pathogen. Herein we
describe 2 TIMP-like proteins in the N. americanus
secretome, both notable for their homology to mole-
cules responsible for the regulation of chronic and
acute inflammation in several mammalian species,
including humans. One of these proteins, subsequently
named Na-AIP-1, displayed potent immunomodulatory
properties in suppressing inflammatory pathology in
distinct murine models of colitis, as well as ex vivo sup-
pression of TNF signaling in a human M1 macrophage
cell line.
In the TNBS-induced model of acute chemically-
induced colitis, prophylactic i.p. delivery of Na-AIP-1
protected against inflammatory pathology. This was
demonstrated across immunologically distinct murine
strains, where efficacy is most apparent when Na-AIP-
1 is provided prior to disease onset, since administra-
tion of Na-AIP-1 after TNBS administration had lim-
ited efficacy. Together, these findings suggest that Na-
AIP-1 may be more suited as a preventative treatment
for colitis, or as a maintenance therapy to prevent dis-
ease reactivation. The prophylactic efficacy of Na-AIP-
1 appears to be dependent on the presence of CD11c+
cells, similar to what has been reported for a related
hookworm-secreted protein Ac-AIP-2 in an asthma
model.13 The precise mechanisms by which Na-AIP-1
acts via CD11c+ cells to exert its immunomodulatory
effects remain undefined, and further studies are
required to determine if Na-AIP-1 induces tolerogenic
DC populations, similar to Ac-AIP-2, as well as the
action of other CD11c+ cells such as macrophages.
In the T cell transfer model of murine colitis, pro-
phylactic delivery of Na-AIP-1 was similarly able to
curtail inflammation and reduce the presence of inflam-
matory CD4+ T cells in the colon. Transcriptional pro-
filing of the colon tissue-specific immunomodulatory
response induced by Na-AIP-1 in the T cell transfer
colitis model revealed multiple anti-inflammatory bio-
logical pathways that are shared with anti-IL-12/23p40
mAb treatment. However, Na-AIP-1 appeared to
uniquely influence several biological processes,including the upregulation of steroid hormone biosyn-
thesis and fatty acid metabolism, and the suppression
of NK cell-mediated cytotoxicity (granzymes primar-
ily) and inflammatory cytokine signaling pathways.
Patients with UC display high levels of granzyme M
(GrzM) mRNA in inflamed colon tissue.47 Moreover,
granzyme B-expressing mucosal B cells were more
prominent in CD and UC patients compared to normal
gut intestinal mucosa,48 suggestive of a role for these
cells in IBD-dependent epithelial damage. While a
direct link to NK cells has not yet been established,
Na-AIP-1 might act directly on NK cells, or indeed
other granzyme-secreting cells, to suppress their cyto-
toxic properties, and this warrants exploration in the
future.
The expectation was that Na-AIP-1 would act simi-
larly to netrin domain-containing homologs isolated
and cloned from the secretions of canine hookworms,
and induce a proregulatory immune environment. Nav-
arro et al13 described a mechanism by which i.p.
administration of Ac-AIP-2 led to an expansion in
CD11c+ DC populations in mesenteric lymph nodes,
correlating with an increase in tolerance-inducing reti-
naldehyde dehydrogenase activity. Treatment with Ac-
AIP-2 was also associated with an increase in FoxP3+
TREG cell populations at mucosal sites, and a reduction
in proinflammatory cytokines. Similarly, Ferreira et
al26 demonstrated suppression of Th1/Th17-associated
cytokines in TNBS-induced colitis following Ac-AIP-1
treatment, as well as an upregulation in IL-10 accom-
panying increased proliferation of TREG cells in the
colon at termination. Herein, Na-AIP-1 was also able
to potently suppress proinflammatory Th1 cytokines,
including TNF, and minimize inflammatory pathology
in both colitis models; yet, some inconsistencies
emerged in the effects of these two proteins on leuko-
cyte populations. While we did not quantify TREG pop-
ulations in the TNBS-induced colitis studies included
herein, FoxP3 transcription was not enhanced in the
intestinal transcriptome of Na-AIP-1-treated RAG KO
mice 27 days after receiving adoptive transfer of CD4+
CD25- T cells, despite the mice being protected against
colitis. However, the duration of the adoptive transfer
model must also be considered; it is possible that TREG
proliferation may have occurred earlier in the progres-
sion of the disease, which had since subsided. Further
research is required to determine whether the mecha-
nism of immunosuppression of Na-AIP-1 is associated
with promotion of TREG responses, or is dependent on
other mechanisms.
What little is understood regarding this family of
unique molecules seemingly confounds expectations
based on current information; to our knowledge, they
remain the only N-terminal netrin domain bearing
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lian TIMPs, to which they display a high level of
sequence conservation, and similarly modulate inflam-
mation. Yet, helminth-derived TIMP-like proteins
show no evidence of MMP binding or inhibition in the
exertion of their anti-inflammatory effect. A compre-
hensive characterization of the crystal structure of
Ancylostoma ceylanicum AceES-2 confirmed the
TIMP-like homology of the N-terminal netrin domain,
but recombinant AceES-2 did not inhibit any of the 10
most abundant human MMPs.23 Moreover, the authors
concluded that the structure of AceES-2 prevented
access of the N-terminus of the protein to the active
site cleft of MMPs, and therefore the protein was
highly unlikely to function as a true TIMP. An addi-
tional level of complexity is added when considering
NECAME_13168; despite a high level of homology
with Na-AIP-1 and a similar elevated transcription dur-
ing the infectious stage of the parasitic life cycle,
recombinant NECAME_13168 did not display anti-
inflammatory properties, suggesting either no immuno-
modulatory influence, or a potential lack of suitability
for recombinant production in the P. pastoris system.
The likely physiological role of NECAME_13168
remains unclear at this stage, and potentially in contra-
diction to other TIMP-like hookworm proteins. How-
ever, identification of sequence or morphological
divergences from Na-AIP-1, Ac-AIP-1 and Ac-AIP-2
may assist in the determination of regions contributing
to anti-inflammatory activity.
Our findings demonstrate the prophylactic efficacy
of recombinantly produced Na-AIP-1 in the ameliora-
tion of clinical and histological indicators of colitis in 2
distinct murine models of IBD. In the chemically-
induced TNBS model of acute colitis, this effect is
dependent on the presence of CD11c+ APCs. In the
CD4+ CD25- adoptive transfer-induced model of
chronic colitis, where inflammation is instigated by a
disruption in T cell homeostasis, prophylactic adminis-
tration of Na-AIP-1 induces a transcriptomic profile
that correlates with a downregulation in metabolic and
signaling pathways associated with Th1 inflammation.
Whether Na-AIP-1 exhibits therapeutic efficacy at lim-
iting active disease in this model was not determined,
and should be the subject of future investigation. Fur-
ther, it is unclear if the choice of the CD4+ CD25-
model of T-cell transfer colitis may have affected the
experimental outcomes, due to the heterogeneous
nature of the transferred T cells. Future studies could
investigate the efficacy of Na-AIP-1 in the more widely
published CD45RBhi T cell transfer model,49 where
pure populations of naı̈ve T cells are transferred, which
may provide additional insight into the cellular mecha-
nisms of how Na-AIP-1 suppresses colitis. While theelucidation of the molecular mechanism remains elu-
sive, Na-AIP-1 nonetheless presents as an excellent
candidate for further clinical development. Suppression
of TNF secretion by human THP-1-derived M1 macro-
phages is encouraging and suggests that the anticolitic
properties of Na-AIP-1 in mice might indeed translate
into human IBD. The identification of binding partners
and the characterization of the pharmacokinetics
involved in Na-AIP-1 metabolism are fundamental in
the determination of its potential for development as a
novel biologic. Future work should further explore the
impact of Na-AIP-1 on human tissues ex vivo, includ-
ing APCs from gut biopsies of IBD patients.
Whilst several studies have been published detailing
the potential of hookworm-derived products in the
TNBS and DSS models of murine colitis,26,50,51 this is
the first report of the prophylactic efficacy of a hel-
minth-secreted protein in the robust murine T cell
transfer model of colitis, which closely resembles
human disease. Further, the discovery of a potential
anti-inflammatory therapeutic from an anthropophilic
parasite like the human hookworm N. americanus, as
well as ex vivo bioactivity with a human macrophage
cell line, may favor a greater safety profile if eventually
translated to humans as a maintenance or preventative
therapy. As such the studies contained within represent
an exciting progression in development of helminth ES
products as human biologics.ACKNOWLEDGMENTS
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